Integrated Investment Consultants LLC Reduces Position in Amgen Inc. (NASDAQ:AMGN)

Integrated Investment Consultants LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,739 shares of the medical research company’s stock after selling 87 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Amgen were worth $714,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. B & T Capital Management DBA Alpha Capital Management increased its position in shares of Amgen by 4.6% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 14,157 shares of the medical research company’s stock valued at $3,690,000 after buying an additional 623 shares during the period. O Keefe Stevens Advisory Inc. grew its holdings in shares of Amgen by 1.0% during the 4th quarter. O Keefe Stevens Advisory Inc. now owns 48,008 shares of the medical research company’s stock worth $12,513,000 after acquiring an additional 457 shares during the period. Sax Wealth Advisors LLC bought a new position in shares of Amgen in the 4th quarter worth approximately $252,000. Somerset Trust Co raised its position in shares of Amgen by 3.3% in the 4th quarter. Somerset Trust Co now owns 19,183 shares of the medical research company’s stock worth $5,000,000 after acquiring an additional 621 shares in the last quarter. Finally, Merit Financial Group LLC lifted its stake in shares of Amgen by 31.3% in the 4th quarter. Merit Financial Group LLC now owns 18,643 shares of the medical research company’s stock valued at $4,859,000 after purchasing an additional 4,447 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 1.0 %

Shares of Amgen stock opened at $272.11 on Friday. The company has a market cap of $146.27 billion, a price-to-earnings ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company’s 50 day moving average is $275.01 and its 200 day moving average is $307.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the company posted $4.96 earnings per share. Amgen’s revenue was up 23.2% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 115.24%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research reports. Wells Fargo & Company decreased their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a report on Friday, January 10th. Piper Sandler lowered their price target on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Royal Bank of Canada dropped their price objective on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Barclays raised their target price on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.